Video Series

Emma Ciafaloni, MD, FAAN, describes the key differences among viral vectors used in gene therapy, highlighting their applications and strengths in targeting specific diseases.

Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.

An expert provides insights into the cost of misdiagnosed Demodex blepharitis and payer considerations for a potential cost-effective treatment.

Explore the facilitation of novel therapy access for desmoid tumors and discover emerging treatments reshaping the landscape.

The criticality of patient education in BTKi use and its impact on treatment adherence is discussed.

Aaron Gerds, MD, MS, reviews the National Comprehensive Cancer Network (NCCN) guideline categories, including evidence, and recommendations for symptomatic high-risk myelofibrosis. He discusses considerations for selecting JAK inhibitors and the threshold for switching treatments based on responses.

Discover how medical institutions provide education on desmoid tumors, ensuring patient referrals and expanding access to innovative therapies.

Eric D. Donnenfeld, MD; discusses the importance of understanding the pathogenesis of Demodex blepharitis to reach a proper diagnosis.

Experts evaluate the financial impact experience by patients receiving BTK inhibitor therapy.

Experts delve into the fundamentals of gene therapy, covering in vivo and ex vivo methods, and explore cellular function targets for effective treatment of a disease.

Mirna Chehade, MD, MPH, discusses ongoing trials for emerging therapies in eosinophilic esophagitis (EoE), her views on the use of combination therapies, and the importance of shared decision-making for the chronic management of EoE throughout the different phases of a patient’s life.

Experts delve into practical aspects of using elacestrant in later-line treatment of patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer, including testing for ESR1 mutations, evaluating efficacy, and monitoring for toxicity.

Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment.

A review of insurance policies for Demodex blepharitis treatments, along with an analysis of the potential toxicities associated with these treatments.

Clinicians explore disparities and similarities in desmoid tumor treatment approaches between academic and community settings, considering access to clinical trials, shared decision-making, and patient education for better outcomes.

Medical experts illustrate the impact of combination therapy for treatment of CLL and SLL.

Aaron Gerds, MD, MS, discusses key updates in the National Comprehensive Cancer Network (NCCN) guidelines for myelofibrosis, including new treatments such as momelotinib and refined recommendations for different patient populations. He reviews symptom management, spleen size, and supportive care measures for optimal patient outcomes.

Delve into the NCCN guidelines and contemporary treatments for desmoid tumors and explore the multidisciplinary approach, limitations, and current standard care options for enhanced patient outcomes.

With their closing thoughts, the panelists provide their key takeaways from this discussion surrounding the operationalization of bispecifics.

Experts underscore cost relief of bispecific antibodies via medication assistance programs.

Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape.

Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.

Mirna Chehade, MD, MPH, discusses the challenges faced by patients with eosinophilic esophagitis (EoE), including the absence of predictive factors for personalized treatment, the social implications of dietary restrictions, and the need for invasive procedures, while emphasizing the importance of regularly scheduled follow-up visits to address medical, nutritional, and psychosocial factors for better outcomes.

Health care professionals review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) multiple myeloma revelations, spotlighting transformative trials, groundbreaking translational research, and clinical perspectives that illuminate the evolving treatment landscape.

Experts discuss the evolving landscape of multiple myeloma treatment, exploring real-world evidence's role in shaping the future and its impact on clinical decisions, rare subgroups, and treatment sequencing.

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and discuss unmet needs in this patient population. They also describe options for mutation and resistance marker testing to guide treatment selection.

Safety considerations for BTKi use in CLL and SLL treatment are highlighted.

Dr Haumschild drives a discussion surrounding the role of bruton kinase inhibitors for treating CLL and SLL.